Literature DB >> 11099220

Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties.

F Sasse1, H Steinmetz, J Heil, G Höfle, H Reichenbach.   

Abstract

New cytostatic compounds, tubulysins, were isolated from the culture broth of strains of the myxobacteria Archangium gephyra and Angiococcus disciformis. The compounds are peptides partly consisting of unusual amino acids and are distantly related to the dolastatins. The tubulysins were not active against bacteria and only little against fungi, but showed high cytostatic activity against mammalian cell lines with IC50 values in the picomolar range. An incubation with 50 ng/ml tubulysin A led to a complete disappearance of the microtubuli network of the cells within 24 hours. The more active tubulysin D induced multipolar spindles: At 0.5 ng/ml all mitotic cells showed more than four spindle poles.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11099220     DOI: 10.7164/antibiotics.53.879

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  40 in total

1.  2-(3'-Indolyl)-N-arylthiazole-4-carboxamides: Synthesis and evaluation of antibacterial and anticancer activities.

Authors:  Mukund P Tantak; Jing Wang; Rajnish Prakash Singh; Anil Kumar; Kavita Shah; Dalip Kumar
Journal:  Bioorg Med Chem Lett       Date:  2015-08-06       Impact factor: 2.823

2.  Chemotherapeutic evaluation of a synthetic tubulysin analogue-dendrimer conjugate in c26 tumor bearing mice.

Authors:  William C Floyd; Gopal K Datta; Shinichi Imamura; Heidi M Kieler-Ferguson; Katherine Jerger; Andrew W Patterson; Megan E Fox; Francis C Szoka; Jean M J Fréchet; Jonathan A Ellman
Journal:  ChemMedChem       Date:  2011-01-03       Impact factor: 3.466

Review 3.  Analysis of myxobacterial secondary metabolism goes molecular.

Authors:  Helge B Bode; Rolf Müller
Journal:  J Ind Microbiol Biotechnol       Date:  2006-02-21       Impact factor: 3.346

4.  Anti-angiogenic effects of the tubulysin precursor pretubulysin and of simplified pretubulysin derivatives.

Authors:  S Rath; J Liebl; R Fürst; A Ullrich; J L Burkhart; U Kazmaier; J Herrmann; Rolf Müller; M Günther; L Schreiner; E Wagner; A M Vollmar; S Zahler
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

5.  The tubulysin analogue KEMTUB10 induces apoptosis in breast cancer cells via p53, Bim and Bcl-2.

Authors:  Oluwafunmilayo F Lamidi; Monica Sani; Paolo Lazzari; Matteo Zanda; Ian N Fleming
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-30       Impact factor: 4.553

Review 6.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

7.  Molecular and functional characterization of myxobacteria isolated from soil in India.

Authors:  Shiv Kumar; Arun Kumar Yadav; Priyanka Chambel; Ramandeep Kaur
Journal:  3 Biotech       Date:  2017-05-31       Impact factor: 2.406

8.  Perspectives from nearly five decades of total synthesis of natural products and their analogues for biology and medicine.

Authors:  K C Nicolaou; Stephan Rigol
Journal:  Nat Prod Rep       Date:  2020-04-22       Impact factor: 13.423

9.  Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.

Authors:  Carolyn A Leverett; Sai Chetan K Sukuru; Beth C Vetelino; Sylvia Musto; Kevin Parris; Jayvardhan Pandit; Frank Loganzo; Alison H Varghese; Guoyun Bai; Bin Liu; Dingguo Liu; Sarah Hudson; Venkata Ramana Doppalapudi; Joseph Stock; Christopher J O'Donnell; Chakrapani Subramanyam
Journal:  ACS Med Chem Lett       Date:  2016-08-26       Impact factor: 4.345

Review 10.  Isolation, biology and chemistry of the disorazoles: new anti-cancer macrodiolides.

Authors:  Chad D Hopkins; Peter Wipf
Journal:  Nat Prod Rep       Date:  2009-03-11       Impact factor: 13.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.